Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.56 |
| ▸ | MST1R | Q04912 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | HGF | P14210 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794406 | 0.90 | MET (0.47) | METMST1RKDRFGFR2HGF | |
| SCHEMBL3917280 | 0.81 | FGFR2 (0.64) | METMST1RKDRFGFR2HGF | |
| SCHEMBL2856123 | 0.80 | MET (0.66) | METMST1RKDRFGFR2HGF | |
| SCHEMBL3923704 | 0.79 | MET (0.56) | METMST1RKDRFGFR2HGF | |
| SCHEMBL15338419 | 0.79 | SRC (0.70) | METMST1RKDRFGFR2PDGFRA | |
| SCHEMBL30216648 | 0.78 | EGFR (0.63) | METMST1RKDRFGFR2PDGFRA | |
| SCHEMBL15326133 | 0.78 | FGFR2 (0.60) | METMST1RKDRFGFR2PDGFRA | |
| SCHEMBL4458664 | 0.78 | FGFR2 (0.60) | METMST1RKDRFGFR2PDGFRA | |
| SCHEMBL3913728 | 0.78 | EGFR (0.63) | METMST1RKDRFGFR2PDGFRA | |
| SCHEMBL6431113 | 0.78 | FGFR2 (0.60) | METMST1RKDRFGFR2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | claimed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | MET 563/4885MST1R 413/4885KDR 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.